REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Notice of Results

MaxCyteAnnouncement

07/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250207:nRSG2613Wa&default-theme=true

RNS Number : 2613W  MaxCyte, Inc.  07 February 2025

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March
11, 2025, and Participate in Upcoming Investor Conference

 

ROCKVILLE, MD, February 7, 2025 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a
leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and commercialization of
next-generation cell therapeutics, today announced that it will release
financial results for the fourth quarter and full year 2024 after the U.S.
market close on Tuesday, March 11th, 2025. Company management will host a
conference call to discuss financial results at 4:30 p.m. Eastern Time.

 

Earnings Conference Call Details

Investors interested in listening to the conference call are required to
register online
(https://register.vevent.com/register/BI510e38b9cbc149a4ab211a0d11e16557) . It
is recommended to register at least a day in advance. A live and archived
webcast of the event will be available on the "Events" section of the MaxCyte
website at https://investors.maxcyte.com/ (https://investors.maxcyte.com/) .

 

Company management will also participate in the following investor conference:

·    45(th) Annual TD Cowen Healthcare Conference

Fireside Chat on Monday, March 3(rd) at 10:30a.m. ET

 

A live and archived webcast of the Cowen fireside chat will be available on
the "Event" section of the MaxCyte investor relations website at
https://investors.maxcyte.com/ (https://investors.maxcyte.com/) .

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 25 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more
at maxcyte.com
(https://www.globenewswire.com/Tracker?data=VYz5wLS7zaAAoN9LcLPBR4K2MnQZ7IsnPHU-Z7siYzZvtH_081o4EbGn3c1jQFc0JVUZlfM5I10g6XpeYFABe57YicaMkwUAVkNifWQuvsYUB7YHJmaI8gpitgEIayD7BcXPat283B53SQ2dZCy0QuYBo9BNxBlrUuD4tfgCuL1nWW3-_mGuvDnufc5FbnusLXrOxvAYXInVbl5WylYNwz1CJ3dNpy8g8IKg3sizT6LyUM1jczb-H2K4bMtFuwTDczuPL84V5nE1ZEJMQjllUClDOoHO1Vg9BapCdoj06aBZ-_0drNUy9pPrGgiYLWTNBrN6IqqKQNHBTuSYA0wOlDaAjtPRlbou81yPGCxdzYdcdAaydDjiEs4a89ghd749)
 and follow us on X
(https://www.globenewswire.com/Tracker?data=IbRJmFs-y6pmwrAyLFg0mBnvpwSn8mJ8PicnKQyM5DTUN2UqSB2u2I6lhcod3y91qEb9XeJ-LH6zEKvBufEzIhVe5vzIj9qvJ9d2Z362sJW4Z3hBoQikJwHZm-2BArfT4O4JYOb2ptDQ4AYJjIllHJbcsajTS4uqIBOibIoxLnF3_Ab01p2mDmpFkutg4yxfDRVyc2hfslMZEtnZ0tGgG4fq4xi0msknRTxNNy6Qd5ZMA7TW97ToXvKHqpk3Wwtz8Zkq1UEbrpLE3JvclNckuunrZLIhLhznZu5Wzl6nrOu8nn0OqImPz_nUmXosXzxt91UValO4GN447t6C3p3_JwWcyZHLK_mJ443JQwWL_bAyXs7yi6Zoic9bUMHS9yQf)
 and LinkedIn
(https://www.globenewswire.com/Tracker?data=x6qH8WZauZRry1BDg_FTfWfdxBynO-n3z9TGSjgV1E3rFwfdpbA5EYfK1AACMZURFIjjj7ifHiSmZj6ojTv_ff6ZqAnV3-buNxCZ-IfST5BpHAW44yrh7Dw9iK0AcjERb05mN-dFQIqirR-fhsubtwgVeArvfNldbRbsxQ6Yk2sS18qH4KJZGow01s6NAz_ua9JDOurVdG9ScE6J8nUf-c7jk2wwdCwLBdeAS_WXKE0Qpgvg_KLzKtse0Flc7uPZhrqSI8IRD96w12x-VXP4HapTfm6MmgrzkkZbyfHo7YS3dLB7lg2hOrvOJ8ojsxyMqQUujJHacfK0i7PtV-nOD6hYY6rjxVVRh89BDxi8kmU9viJiNTZAFB7fGFaL0y_NkXLCp1tvNdIaOnGVl_MfCw==)
.

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com
(https://protect.checkpoint.com/v2/___https:/www.globenewswire.com/Tracker?data=P6_WcNBTuSpAskxTjScd7ScigYxiD1QdFiLCAgfAnNpDSBQjkoZoeGbKDbT4wVLlo8T3Z9RXNbzPuTP4fN_NiQ==___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzplNzA0NWQ4MTM2NGE5NzVjZjM2NWQ2NzdjYTA4YWMyODo2OmFiNDM6ZDI3YmI0ZDU1ZjkyMTdmODgyNDZkZDFkMmI5ODJiNzE3MjMyZDc1MThjNzljMTE4Y2FmZmViYTRhMTAzY2EyMTpwOlQ6Rg)

US Media Relations

Spectrum Science

Jordan Vines

+1 540-629-3137

jvines@spectrumscience.com
(https://protect.checkpoint.com/v2/___https:/www.globenewswire.com/Tracker?data=GjgdBvzBPoSo4Gfz57YWdQpZc47BZnCkXrdvRee1r2xZdZQ43JSi1lOU7Lfyr6lJ0pnF0IANTSruoTMmHuCKWcSD97sMLAPba3jGz9k6PvWM9kswL5cXQhD9aO4vlvXI___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzplNzA0NWQ4MTM2NGE5NzVjZjM2NWQ2NzdjYTA4YWMyODo2OjVlOGQ6ZmNjZTJjYTgwZDJlOTM0OTIwYzE4NmRhNmIwYzE5YmZkYTA2N2I0NjcxODdlOTU2NjQxOGU0ODNmOGM2MDkyNDpwOlQ6Rg)

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

UK IR Adviser

ICR Healthcare

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@icrhealthcare.com
(https://protect.checkpoint.com/v2/___https:/www.globenewswire.com/Tracker?data=XLnMCc6YRZ3sNJujVZPY5hRBJNKjpDl8VkkYD8qL7h15GV5OqlIM8rXEbmn-67eDZfDfNrgeUXeeNAV9JxgzSon3860ys0E_Qg8Fhde5RkGhTbRGu22bEHW7a-QIAFnf___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzplNzA0NWQ4MTM2NGE5NzVjZjM2NWQ2NzdjYTA4YWMyODo2OjllY2I6MmZkNTQ5M2VlMmMyODdkYTIyZTMyNTAzZTcxZmQ5NTA0ZGM0ODE3MjdmZWE2YmM3NzBiZDhlNDA3NTdmZDBmYzpwOlQ6Rg)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORTFMBTMTIMTIA